Affymetrix, Inc. v. Hyseq, Inc.

I'll research this case thoroughly using web searches.

I have substantial material. Let me verify specifics about the docket number, judge, counsel, and outcome.

Let me pin down the specific docket number and any 1998-1999 filings.

Case Overview — Affymetrix, Inc. v. Hyseq, Inc., N.D. Cal. (San Jose Div.)

The parties. This was a fight between two operating companies, not an NPE/PAE assertion — both sides made and sold the accused technology. Affymetrix, Inc. (Santa Clara, CA; Nasdaq: AFFX) was the DNA-chip spinout of the combinatorial-chemistry firm Affymax and the leading commercializer of the GeneChip® high-density oligonucleotide probe array, built on "VLSIPS" (Very Large Scale Immobilized Polymer Synthesis) photolithographic synthesis; the New York Times in 2001 described it as "the largest maker of gene chips for drug research." Hyseq, Inc. (Sunnyvale, CA; Nasdaq: HYSQ, trading from Aug. 8, 1997) was a genomics/gene-discovery company formed to exploit the sequencing-by-hybridization ("SBH") patents of Radoje Drmanac and Radomir Crkvenjakov, then at Argonne National Laboratory; it sold SBH-based gene-screening services (its largest contracts being with BASF and Chiron) and later the "HyChip" high-density probe array. Affymetrix's own SEC risk factors candidly stated that "Affymetrix will need to be successful in asserting Affymetrix patents in the DNA array field," making this a foundational intellectual-property war between two commercial competitors, in both directions. (Nature Biotech. May 1997; NYT, Oct. 26, 2001; Affymetrix S-3 risk factors)

The accused technology. The dispute ran both ways. In Hyseq's earlier, parallel action (N.D. Cal. No. C 97-20188 RMW, filed March 4, 1997), Hyseq alleged that Affymetrix's GeneChip system — the probe arrays plus the instrumentation and analysis software sold for genetic analysis — infringed its SBH method patents, and that Affymetrix induced customers to infringe. In Affymetrix's mirror-image affirmative case, Affymetrix accused Hyseq's HyChip high-density probe array and its SBH-based genetic-analysis technology; the court characterized the Hyseq dispute as centering on "the use of patented computer technology used to perform different types of genetic analysis" — which maps directly onto the '716 software/analysis patent. The public record is thinner on precisely which Hyseq products and services were named in the infringement contentions, so I would not go further than that. (BioCentury; D. Del. transfer opinion)

The patents asserted. All three asserted Affymetrix patents are siblings in one family, descending by continuation-in-part from Application No. 08/362,901, and each was asserted essentially at issuance: (1) U.S. 5,744,305 ("Arrays of Materials Attached to a Substrate," issued Apr. 28, 1998) — an apparatus claim covering a solid support bearing >400 different oligonucleotides or polynucleotides per cm² in discrete predefined regions with determinable sequences (asserted claims 1, 2, 5, 8, 15, 17, 20 against Hyseq); (2) U.S. 5,795,716 ("Computer-Aided Visualization and Analysis System for Sequence Evaluation," issued Aug. 18, 1998) — computer program products/systems that call an unknown base by comparing hybridization of a probe set to a sample versus a known reference (asserted claims 3, 4, 7, 8, 9, 10); and (3) U.S. 5,800,992 ("Method of Detecting Nucleic Acids," issued Sept. 1, 1998) — methods of detecting nucleic acids on arrays, including simultaneous two-label detection and differential gene-expression measurement (asserted claims 1 and 3). A fourth sibling, U.S. 5,445,934 ("Array of Oligonucleotides on a Solid Support"), was asserted against Incyte but not against Hyseq. Hyseq's asserted counter-patents were U.S. 5,202,231; 5,525,464; 5,695,940; and later 6,018,041 and 5,972,619. (132 F. Supp. 2d 1211, 1217–18 (N.D. Cal. 2001); CourtListener)

Procedural posture and venue. Per the case metadata, Affymetrix filed on Aug. 18, 1998 in the N.D. Cal. San Jose Division as No. C 98-03192, asserting the '305 and '716 patents and amending on Sept. 1, 1998 to add the '992 patent — a chronology that fits perfectly with the issue dates of the '716 (Aug. 18, 1998) and '992 (Sept. 1, 1998) patents. I have a sourcing caveat here: the SEC filings and the published claim-construction opinion identify the Affymetrix-v-Hyseq action as No. C 99-21163 JF before Judge Jeremy Fogel, and Hyseq's later action as No. C 00-20050 RMW before Judge Ronald M. Whyte; I could not retrieve a PACER/RECAP docket for C 98-03192, so whether it was refiled, renumbered, or is a distinct pleading-stage case is unresolved on the accessible record. What is clear: the court consolidated Affymetrix v. Hyseq (C 99-21163 JF) and Affymetrix v. Incyte Pharmaceuticals/Synteni (C 99-21164 JF) for a joint Markman tutorial and hearing on Nov. 29–30, 2000, issuing a single order on Jan. 22, 2001, 132 F. Supp. 2d 1211, with supplemental briefing ordered on "substantially complementary." Venue mattered: both parties and all accused technology were in the district, the same patents were being litigated against Incyte/Synteni in Delaware (where the court denied a § 1404(a) transfer motion, expressly weighing N.D. Cal.'s interest and its "lighter" and "faster" docket), and consolidation let one judge construe the whole Affymetrix array portfolio at once. Affymetrix's counsel was Irell & Manella LLP (Morgan Chu, Richard de Bodo, Jeffrey L. Arrington, Marc A. Fenster); the defense teams listed in the order were from Marshall, O'Toole, Gerstein, Murray & Borun (Chicago) and Latham & Watkins (Menlo Park). (Casetext, 132 F. Supp. 2d 1211; D. Del. transfer opinion; Affymetrix 8-K, Oct. 24, 2001)

Outcome and why it is notable. The case did not go to judgment. On Oct. 24, 2001 the parties signed a comprehensive Settlement Agreement, and on Oct. 26, 2001 jointly filed a Stipulation and Proposed Order of Dismissal and Final Judgment dismissing all three N.D. Cal. actions with prejudice; each side acknowledged the validity and enforceability of the other's asserted patents. Unusually, the deal was not a cash-only settlement but a cross-license-plus-joint-venture: Hyseq contributed its SBH patents to a new subsidiary, Callida Genomics, Affymetrix took an initial 10% equity stake (and reportedly ~$8M in cash plus a $4M, 7.5% loan), and the companies formed N-Mer, Inc. to commercialize a high-speed sequencing chip with Affymetrix as exclusive array/system supplier. The case sits at the center of the late-1990s "gene chip" patent wars and is still cited for two claim-construction propositions: that 35 U.S.C. § 112 ¶ 6 does not apply to "computer code that [performs a function]" claim language, and that a court may not import an opponent's § 112 ¶ 1 enablement arguments into claim construction to narrow claims. Its significance today is historic rather than ongoing: there is no IPR/PTAB linkage — the AIA inter partes review regime did not exist until Sept. 16, 2012, and these patents (earliest filings 1992–1996) have long since expired. The parallel administrative proceeding was a pre-AIA interference, Chee v. Drmanac, Interference No. 104,552, pitting Affymetrix's Mark Chee against Hyseq's Drmanac, which Hyseq resolved by entering an abandonment of contest in November 2001. Hyseq later reorganized into Hyseq Pharmaceuticals and Callida, became Nuvelo, Inc. (2003–04), and its corporate successor chain runs to today's Oruka Therapeutics; Affymetrix was acquired by Thermo Fisher Scientific in 2016. (Affymetrix 8-K; Hyseq 10-K (2001), Item 3; NYT)

Open items / sourcing caveats

• The relationship between metadata's C 98-03192 and the publicly reported C 99-21163 JF is not documented in the sources I could reach; PACER/Recap access to the 1998 docket was unavailable to me.
• I could not verify a discrete final judgment figure (none appears to exist — the case ended in a with-prejudice dismissal, not a judgment).
• Which specific Hyseq products/services were named in Affymetrix's infringement contentions beyond the "HyChip" array and its analysis software is not clearly sourced.
• Counsel rosters above are as listed in the Jan. 22, 2001 order; the order does not cleanly map each firm to a specific defendant in the consolidated cases.

I'll research this case systematically across dockets, opinions, and secondary sources.

Let me dig deeper into the specific docket, the consolidated Markman order, and the 2001 settlement.

Good progress. Let me pin down the docket number linkage and the full procedural history.

Affymetrix, Inc. v. Hyseq, Inc., No. C 98-03192 (N.D. Cal.) — Chronology of Key Legal Developments

Sourcing note / caveat up front: I could not pull the actual PACER docket (no live PACER access), so the docket-event timeline below is reconstructed from court opinions, SEC filings (Affymetrix 10‑K; Hyseq 10‑K and exhibits), company press releases, and trade press (BioCentury, NYT/Bloomberg). Where a date or detail is inferred rather than documented, I say so.

One important number discrepancy to flag: the October 2001 consolidated claim‑construction opinion reported at 132 F. Supp. 2d 1212 is indexed under docket numbers C 99‑21163 JF and C 99‑21164 JF (Judge Fogel), not C 98‑03192 — yet the opinion's caption includes Hyseq as a defendant/counterplaintiff and construes the '716 patent, which was asserted only against Hyseq. That strongly suggests the Hyseq action was reassigned/renumbered (see the judge changes below) and consolidated with the Synteni/Incyte cases for Markman purposes. I could not verify the renumbering on PACER, so treat the C‑number linkage as high‑confidence but unconfirmed.

---

1. Filing and initial pleadings (1998)

• 1998‑08‑18 — Affymetrix filed suit against Hyseq in the U.S. District Court for the Northern District of California (San Jose Division), Case No. C 98‑03192, alleging infringement of U.S. Patent 5,795,716 ('716, computer‑aided sequence evaluation) and U.S. Patent 5,744,305 ('305, high‑density oligonucleotide arrays). (Hyseq press release, via Free Library; Affymetrix 10‑K.)
• 1998‑09‑01 — Affymetrix filed an amended complaint adding U.S. Patent 5,800,992 ('992, method of detecting nucleic acids), asserting claims 1 and 3 against Hyseq. (Hyseq press release; 132 F. Supp. 2d at 1216–18.)
• Hyseq's response — Hyseq publicly stated the suit "is without merit and intends to vigorously defend." The 2001 opinion caption lists Hyseq as "Defendant and Counterplaintiff," so Hyseq pleaded counterclaims (the counterclaim pleading itself is not dated in any source I could retrieve).
• Affymetrix 10‑K characterization — Affymetrix described the Hyseq action (along with the OGT action) as seeking damages and an injunction and acknowledged it "may not prevail."

Related/parallel lawsuits (context for the settlement):

• March 1997 — Hyseq sued Affymetrix in N.D. Cal., Case No. C‑97‑20188 RMW (PVT) (Judge Whyte), asserting U.S. 5,202,231 and U.S. 5,525,464 (sequencing‑by‑hybridization).
• December 1997 — Hyseq's second suit (C‑97‑4469, Judge Eugene Lynch per the "THE" initials), asserting U.S. 5,695,940; consolidated with the first case before Judge Whyte.
• 1998‑01‑06 — Affymetrix sued Incyte/Synteni in D. Del. (No. 98‑6) on the '934 patent; 1998‑09‑01 it added '305 and '992 in D. Del. Those actions were transferred to N.D. Cal. on 1998‑11‑18 as C 98‑4507 and C 98‑4508. See Affymetrix, Inc. v. Synteni, Inc., 28 F. Supp. 2d 192 (D. Del. 1998) (transferring; weighing "center of gravity," inventor/witness/document locations, and Affymetrix's reincorporation in Delaware).

---

2. Pre‑trial motions and procedural milestones in the Hyseq action

• 1999‑06‑30 — The court granted Hyseq's motion for a 120‑day extension of the case‑management schedule. (Hyseq press release.)
• 1999‑07‑01 — Judge Fern Smith began a planned leave of absence.
• 1999‑08‑19 — C 98‑03192 was reassigned to Judge William H. Alsup.
• 1999‑09‑21 — Judge Alsup invited the parties' positions on consolidating the claim‑construction hearing and technology tutorial in the Hyseq case with Affymetrix v. Synteni. The construction eventually issued from Judge Fogel (C 99‑21163/21164 JF), indicating a further reassignment.
• No motion to dismiss / transfer / § 1292 stay appears in the Hyseq action in any source I found. (The transfer fight was litigated in the Synteni/Incyte Delaware case, not against Hyseq.)
• In the parallel Synteni/Incyte case (relevant because it was consolidated with Hyseq for Markman): on 1999‑05‑04 the court denied without prejudice Affymetrix's motion for a preliminary injunction on the '992 patent and denied Incyte/Synteni's summary‑judgment motion that certain '992 claims were invalid; on 1999‑05‑06 Incyte/Synteni moved to stay pending USPTO interference, which was denied on 1999‑05‑07. (Affymetrix 10‑K.)

---

3. Claim construction (Markman)

*A. The Hyseq/Synteni/Incyte consolidated Markman — Affymetrix, Inc. v. Hyseq, Inc., 132 F. Supp. 2d 1212 (N.D. Cal. 2001)* (2001 WL 128440; Judge Fogel). Affymetrix asserted:

Key constructions and holdings:

• Framework — Claim construction is a question of law for the court; intrinsic evidence controls; a party's non‑enablement argument is not a proper basis for narrowing a claim term. The court repeatedly refused to "import extraneous limitations" from the specification, and expressly declined to redraft claims to preserve validity.
• "oligonucleotides" — polymers of nucleotides, roughly 2 to about 100 nucleotides (no 12‑mer lower bound).
• "polynucleotides" — polymer of nucleotides of length two or more (rejecting Hyseq's "longer than twelve").
• "array"/"predefined region"/"discrete known region" — adopted the '934 specification's definition of "region" (a localized area on a surface which is, was, or is intended to be activated for formation of a polymer); "activated" = exposed to an energy source rendering a group active; "formation" held to cover both synthesis and immobilization of preformed polymers (driven by the caged‑binding‑member embodiment), after checking the prosecution history for disclaimer.
• "determinable sequence" — a sequence that can be determined (rejecting Hyseq's monomer‑by‑monomer/VLSIPS‑only construction).
• '992 "detecting nucleic acid sequences" — "determining the presence or absence of two or more nucleic acid molecules"; the court agreed with Hyseq and against Incyte that the claim is not limited to sequencing applications.
• '992 "a first [or second] collection of labeled nucleic acid" — an aggregation/accumulation of labeled nucleic acids; the court rejected Hyseq's "non‑identical molecules" limitation.
• '716 "computer code" — held to recite structure ("not a generic term, but rather recites structure … understood by those of skill in the art to be a type of device for accomplishing the stated functions") — a holding later cited in § 112 ¶ 6 / Williamson debates.
• Deferred: the court did not construe "a sequence substantially complementary" at that time, ordering further briefing. This became the pivotal indefiniteness battleground (see § 5).

B. The Hyseq v. Affymetrix Markman (Judge Whyte) — a separate track: Markman order 1999‑10‑27, in which the court rejected Affymetrix's argument that Hyseq's SBH claims were limited to de novo sequencing. After a 2000‑02‑22 clarification hearing, the court issued a clarifying order on/about 2000‑08‑01 holding that (i) "probes" may be labeled or unlabeled, in solution or attached; (ii) "sequencing" = determining the linear order of bases and covers resequencing/polymorphism detection; and (iii) "hybridization conditions" does not require perfect differentiation. (Hyseq press release, Aug. 1; year inferred as 2000 from the February 2000 hearing.)

---

4. Discovery milestones of strategic significance

The record here is thin in public sources; what is documented:

• The D. Del. transfer opinion, 28 F. Supp. 2d 192, canvassed the parties' expected trial witnesses (Fodor, Read, Stryer, Pirrung, Solas, Dower; Brown, Shalon, Davis, Schena, Drmanac) and the location of laboratory notebooks — evidence that document/witness discovery was a central battleground and drove forum litigation.
• 1999‑06‑30 case‑management extension (120 days) — a schedule slip I could date.
• Affymetrix's 10‑K repeatedly states it "expended and is likely to continue to expend substantial financial and managerial resources" on these cases.
• I found no documented discovery sanctions order, adverse‑inference ruling, or privilege fight in C 98‑03192.

---

5. Motions practice after Markman and the indefiniteness fight

• In briefing around February 2001, Incyte (joined by Hyseq in parallel) pressed that "substantially complementary" was indefinite under § 112 ¶ 2, pointing out that no journal article in 45 scientific databases since 1965 used the term for nucleic acids, that the specification contained no definition, and that an Affymetrix application had been rejected as indefinite for using it. Affymetrix countered with the specification's stringency conditions and Regents of the Univ. of Cal. v. Oncor, Inc., 44 U.S.P.Q.2d 1321 (N.D. Cal. 1997). (Germeshausen Center "Microarray Battle" newsletter; BioCentury.)
• A case‑management conference was set for 2001‑07‑16, and the court's construction of "substantially complementary" was still "forthcoming" as of that reporting.

---

6. Trial, verdict, post‑trial motions, appeal

There were none. No trial, verdict, JMOL, new‑trial, or fee motion in C 98‑03192 is documented in any source I could reach, and I found no Federal Circuit appeal. The case ended by settlement while claim construction and the indefiniteness dispute were still being resolved.

---

7. Final disposition — the October 2001 global settlement (the key outcome)

• 2001‑10‑24 — Hyseq, Inc. (Nevada corp., Sunnyvale, CA) and Affymetrix, Inc. (Delaware corp., Santa Clara, CA) executed a Settlement Agreement (effective date October 24, 2001), filed publicly as Exhibit 10.20 to Hyseq's SEC filings.
• 2001‑10‑25/26 — Announced publicly: the parties settled all patent infringement lawsuits and legal actions between them dating to 1997, and agreed to form a joint venture, "N‑Mer," a subsidiary of Hyseq's newly created Callida Genomics unit, to develop high‑speed DNA sequencing chips using both companies' technology. (NYT/Bloomberg, Oct. 26, 2001.)
• Terms: mutual general releases and covenants not to sue (including releases running to customers/users of Affymetrix microarray products), representations of exclusive ownership of the respective patent portfolios ("Hyseq Patents"/"Affymetrix Patents"), and non‑exclusive, royalty‑bearing and internal‑use cross‑licenses across the portfolios (per the agreement and the Hyseq 10‑K; the licenses and consideration are partly redacted).
• Economic footprint: Hyseq's 10‑K reports $0.8 million in 2001 contract revenue under its agreement with Affymetrix.
• Practical effect: the '305, '992 and '716 patents (and Hyseq's '231/'464/'940) were licensed rather than adjudicated. As one IP retrospective put it, Affymetrix never established Hyseq/Incyte infringement liability because "the parties opted to settle their litigation."

Companion instruments executed the same day:

• Interference Settlement Agreement (2001‑10‑24) resolving Interference No. 104,552 among Affymetrix U.S. 5,795,716 and 5,974,164 and Hyseq Application 09/358,875: no preliminary motions/statements; Hyseq agreed to file an abandonment of contest by 2001‑11‑15; each side agreed not to actively seek interferences against the other on specified subject matter; Affymetrix agreed to file the agreement with the PTO under 35 U.S.C. § 135(c).
• Related Incyte settlement (December 2001): Affymetrix paid Incyte $4.5 million for RNA‑amplification technology (U.S. 5,716,785 and 5,891,636); notably, that settlement did not resolve Incyte's BPAI appeal in the interferences with Affymetrix's '305 and '992 patents, which remained pending.

Present posture: the C 98‑03192 litigation is terminated by settlement (releases + cross‑licenses), with the parties' disputes defused rather than adjudicated. I could not retrieve the specific stipulated dismissal order date from PACER.

---

8. Parallel administrative proceedings (interferences — not IPRs)

• 1999‑04‑02 — USPTO notified Affymetrix it had declared a preliminary interference relating to the '992 and '305 patents, based on an application naming Brown et al. (Stanford), allegedly exclusively licensed to Synteni/Incyte. A hearing on whether the interference would proceed was held 1999‑08‑09 with no decision at the hearing. (Affymetrix 10‑K.)
• Interference No. 104,552 — '716 and '974,164 (Affymetrix) vs. Hyseq App. 09/358,875, terminated by Hyseq's agreed abandonment of contest (filed on/before 2001‑11‑15).
• BPAI appeal — Incyte's appeal in the '305/'992 interferences survived the December 2001 Incyte settlement (per the microarray IP retrospective). I found no public record of the final outcome/date.

No PTAB IPR or PGR proceedings exist on these patents — and none could: the litigation closed in 2001, more than a decade before the AIA created IPRs (effective 2012‑09‑16), and the three asserted patents (filed 1994–96) have long since expired. The strategic analogue in this case was the USPTO interference practice, and the settlement's interference‑termination clause shows that practice materially shaped the deal.

---

Bottom line

The litigation followed a classic late‑1990s DNA‑array war arc: 1998 filing → amended complaint → prolonged forum/consolidation maneuvering (Smith → Alsup → Fogel; consolidated with the Synteni/Incyte cases) → a substantive Markman ruling (132 F. Supp. 2d 1212) that broadly favored Affymetrix on claim scope while deferring "substantially complementary" → an intensifying § 112 indefiniteness attack → and a global settlement on 2001‑10‑24 that ended all Affymetrix–Hyseq litigation, cross‑licensed the portfolios, resolved Interference No. 104,552, and launched the N‑Mer/Callida Genomics joint venture. No trial, verdict, judgment, or appeal ever occurred, and there are no IPRs/PGRs to report.

If you can supply PACER access (or the N.D. Cal. docket sheet for C 98‑03192 / C 99‑21163), I can lock down the answer/hard data: pleadings dates, any Rule 12 or transfer motions, the dismissal order, and the exact renumbering chain.

I'll research the counsel of record for Affymetrix in this case. Let me run several searches.

Bottom line

I could not verify counsel of record for Affymetrix in Affymetrix, Inc. v. Hyseq, Inc., No. C 98‑03192 (N.D. Cal.) from the sources I was able to reach. My search budget was exhausted before I could pull the PACER docket sheet or the counsel block of the reported opinion, so I am not going to name attorneys. Per the operating rules, identifying counsel without a source would be fabrication.

What I did verify

The "Livornese Declaration" is the only counsel-adjacent artifact I surfaced. It is cited as an evidentiary declaration (authenticating a prosecution-history exhibit), which is the kind of filing often made by a patent attorney or agent — but I have no source establishing who Mr. / Ms. Livornese represented, their firm, or even their profession. Do not treat that as counsel identification.

Why the gap exists (and how to close it)

• The docket number in the opinion (C 99‑21163 / C 99‑21164) differs from the Hyseq case number (C 98‑03192). The actions were coordinated before Judge Fogel, so counsel for Affymetrix on the Hyseq docket must be read off the C 98‑03192 docket, not the consolidated one.
• I did not reach the RECAP/PACER docket for 3:98‑cv‑03192, so I cannot tell you whether any early filings are sealed, whether Affymetrix used in-house counsel, or whether a substitution of counsel occurred before the 2001 Markman ruling.

Sources that would resolve this, in priority order:

1. PACER / RECAP docket for N.D. Cal. 3:98‑cv‑03192 — the "attorney" tab lists lead and local counsel with firm and address; every appearance has a docket entry.
2. The counsel block printed at the head of 132 F. Supp. 2d 1212 (Westlaw/Lexis) — F. Supp. 2d reports list "Counsel:" for each party as of the 2001 opinion.
3. Affymetrix 10‑K/10‑Q litigation notes (FY1998–2001) and Hyseq 10‑K filings via EDGAR, which sometimes name outside litigation counsel.
4. Law360 / Reuters Legal / The Recorder archives for the 1999–2002 period, and the N.D. Cal. clerk's office case file if the docket is not digitized that far back.

If you can supply the Chapter 11/10‑K exhibits or a PACER pull of the attorney list, I can complete the requested table (name, role, firm/office, and a one-line experience note) for each attorney of record.

I'll research Hyseq's counsel of record. Let me start with several parallel searches.

Let me dig into the docket and specific attorney names.

Bottom line

I could not identify counsel of record for Hyseq, Inc. in Affymetrix, Inc. v. Hyseq, Inc., No. C 98‑03192 (N.D. Cal.). My search budget ran out mid-investigation: my first pass (4 queries) returned nothing on Hyseq's attorneys, and three follow‑up queries were terminated by a step limit before returning results. I am therefore not naming any attorney as "counsel of record" for Hyseq — no source I reached ties a named lawyer or firm to the defense side of this docket. Naming any of the people below as Hyseq's counsel would be fabrication.

This is a materially worse result than the plaintiff‑side section, so treat this section as a negative finding plus a short list of leads, not as an attorney table.

What I verified (and what I did not)

The one lead worth chasing (flagged: NOT verified as counsel in C 98‑03192)

William K. Merkel, Ph.D. — currently Of Counsel, Marshall, Gerstein & Borun LLP, Chicago (312‑474‑6629; wmerkel@marshallip.com). His firm bio lists among his litigated matters:

"Hyseq, Inc. v. Affymetrix, Inc., Civil Action No. C‑97‑20188 (N.D. Cal.)" — https://www.marshallip.com/william-k-merkel-ph-d/ and https://www.marshallip.com/content/uploads/2023/01/Merkel-Bill.pdf

Why this is relevant but not an answer:

• That is the sister case (Hyseq as plaintiff against Affymetrix, filed March 1997 per Nature Biotechnology 15:406, https://www.nature.com/articles/nbt0597-406a.pdf), not the Affymetrix‑as‑plaintiff action C 98‑03192 that this task asks about. Counsel lists can overlap, but a bio entry in a different docket is not proof of an appearance in this one.
• His listed admissions are Illinois, N.D. Ill., and the USPTO — no California or N.D. Cal. admission appears in the bio. If he appeared in the California case at all, it would have been pro hac vice and/or in a patent‑prosecution/technical capacity; the bio does not say which side, which role, or through which firm.
• a plainSite profile page for Hyseq references "marshall‑otoole" (i.e., the predecessor firm Marshall, O'Toole, Gerstein, Murray & Borun), which is at least consistent with a Chicago patent firm having handled Hyseq patent work — but I could not confirm that firm's appearance in C 98‑03192, and I could not confirm Merkel was at that firm during 1998–2001. https://www.plainsite.org/profiles/hyseq-inc/page-2/attorneysmarshall-otoole/
• His bio note ("prosecuted numerous… patent applications… in genomics") plus the Hyseq listing suggests patent prosecution/technical counsel to Hyseq, not necessarily trial counsel of record in this case.

Conclusion: Merkel is a plausible Hyseq-side patent lawyer across the Hyseq–Affymetrix litigation family, and the current firm/location is verifiable. His role in C 98‑03192 is unverified and should not be stated without a docket or opinion counsel block.

New case‑status facts (partially closes the prior section's open question)

The prior section flagged that no final judgment or settlement could be confirmed. The Affymetrix 10‑Q supplies two datapoints that bear directly on how this case ended/inched forward (source: https://capedge.com/filing/913077/0000912057-01-516178/AFFX-10Q-2001Q1):

1. May 8, 2001 — the N.D. Cal. court "determined that the term 'substantially complementary,' as used in the two asserted claims of the '992 Patent[,] is indefinite." If accurate, that is a validity‑adverse ruling against Affymetrix on the '992 claims — a significant win for Hyseq. This is a party characterization (Affymetrix's 10‑Q), not a court citation, so flag it as such; it is also consistent with the Markman opinion's express deferral of the term ("The Court will construe this term following the parties' supplemental briefing with respect to… 'substantially complementary'"). 132 F. Supp. 2d at ~1229.
2. Jan. 30, 2001 — the BPAI declared an interference between Affymetrix's '716 patent claims and certain claims of a Hyseq application. That is a parallel administrative proceeding that existed alongside this litigation (relevant if anyone asks about PTAB‑type history).

Also note the judge history in the 10‑Q/press release (Fogel‑era consolidated Markman; earlier Alsup; earlier still Fern Smith) versus the prior section's observation that the opinion is docketed under C 99‑21163 JF / C 99‑21164 JF. The Hyseq docket number (C 98‑03192) is the one that governs Hyseq's appearances; the reported opinion's caption consolidates all three companies.

Contradictions / caveats to carry forward

• The press release says Affymetrix's original suit asserted "5,795,716 and 5,744,305." The case metadata lists 5,795,716 (i.e., '716) and 5,744,305 — consistent; the "5795716" string in the metadata is the same patent, so no conflict, just formatting.
• The press release also states the original case was filed in the San Jose Division — useful for pulling the right PACER branch.
• The Delaware transfer opinion's references to "counsel for Synteni and Incyte" (a female affiant) and "the attorney representing Dr. Drmanac" (unnamed) are not Hyseq counsel identifications. Affymetrix, Inc. v. Synteni, Inc., 28 F. Supp. 2d 192 (D. Del. 1998), https://www.courtlistener.com/opinion/2531759/affymetrix-inc-v-synteni-inc/.

How to close this (priority order)

1. RECAP/PACER for N.D. Cal. 3:98‑cv‑03192 (San Jose) — the "Attorneys" tab and every appearance entry (notice of appearance, pro hac vice application, substitution). This is the only authoritative source for "of record." Try CourtListener's RECAP docket search by party name "Hyseq."
2. Counsel block of 132 F. Supp. 2d 1212 (Westlaw/Lexis print) — F. Supp. 2d reports a "Counsel:" line for each party as of the 2001 opinion; that would capture Hyseq's lead and local counsel in one place.
3. Hyseq/Nuvelo 10‑K and 10‑Q litigation notes (FY1998–2002) via EDGAR — sometimes name outside litigation counsel; Nuvelo is the post‑2002 successor, which may help date the resolution.
4. Local press/legal archive: The Recorder, San Jose Mercury News, and Law360 (which already surfaced Mark C. Fleming at Bingham McCutchen for the related Synteni docket — https://www.law360.com/firms/bingham-mccutchen/attorneys/mark-c-fleming — but that is a third‑party/related docket, not Hyseq's counsel, and must not be conflated).
5. Confirm or exclude Merkel / Marshall, O'Toole via a CourtListener RECAP pull on both C 98‑03192 and C 97‑20188.